Spero Therapeutics (SPRO) Expected to Announce Earnings on Thursday

Spero Therapeutics (NASDAQ:SPRO) is expected to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $26.00 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Spero Therapeutics Stock Performance

Shares of NASDAQ SPRO opened at $2.46 on Thursday. The stock has a market cap of $138.60 million, a PE ratio of -3.11 and a beta of 1.45. Spero Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $3.22. The stock has a fifty day moving average of $2.37 and a 200-day moving average of $2.29.

Insider Buying and Selling at Spero Therapeutics

In related news, insider Esther Rajavelu sold 87,917 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.36, for a total value of $207,484.12. Following the sale, the insider owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Spero Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in shares of Spero Therapeutics in the 2nd quarter valued at about $100,000. Invesco Ltd. bought a new position in shares of Spero Therapeutics in the second quarter worth approximately $43,000. Vanguard Group Inc. increased its position in shares of Spero Therapeutics by 2.0% in the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock worth $3,741,000 after purchasing an additional 39,474 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Spero Therapeutics in the third quarter valued at approximately $55,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Spero Therapeutics in the third quarter valued at approximately $283,000. 25.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on SPRO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, January 11th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce”.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.